Aspirin 500 MG / caffeine 65 MG Effervescent Oral Tablet — RxCUI 1536815
RxNorm drug concept · Semantic clinical drug
RxCUI 1536815
Semantic clinical drug · SCD
● Current RxNorm concept 2 FDA products
7 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1536815
Official nameAspirin 500 MG / caffeine 65 MG Effervescent Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asASA 500 MG / Caffeine 65 MG Effervescent Oral Tablet
FDA products mapped2
Package NDCs mapped7
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Aspirin Rectal: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Take it out of its plastic packet and insert it into the rectum as far as possible. Adults usually use one every 4 hours, for no more than 10 days, or as your physician directs.
- Children under 12 should only use it after talking to a physician. Children and teenagers who have or are recovering from chicken pox, flu symptoms, or flu should not use it at all...
- Aspirin has been linked to Reye syndrome, a rare but serious illness. If nausea, vomiting, or fever occur, talk to a doctor right away.
- Check with a health professional first if you are pregnant or nursing. It is especially important not to use aspirin in the last 3 months of pregnancy unless your doctor directs it...
🕸️ Concept Web — How Aspirin 500 MG / caffeine 65 MG Effervescent Ora... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Aspirin 500 MG / caffeine 65 MG Effervescent Oral Tablet
RxCUI 1536815 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 3
The active substance itself — no strength, form, or brand attached yet.
-
Aspirin
1191IN -
Caffeine
1886IN -
Aspirin / caffeine
214250MIN
-
Aspirin
-
Dose forms 4
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Aspirin / caffeine Effervescent Oral Tablet
1536814SCDF -
Aspirin / caffeine Oral Product
1153525SCDG -
Effervescent Oral Tablet
1535727DF -
Oral Product
1151131DFG
-
Aspirin / caffeine Effervescent Oral Tablet
-
Clinical & branded drugs 2
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Aspirin 500 MG
315424SCDC -
Caffeine 65 MG
317311SCDC
-
Aspirin 500 MG
Showing up to 8 concepts per family — 9 of 9 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Aspirin 500 MG
SCDC · 315424 -
Caffeine 65 MG
SCDC · 317311 -
Aspirin / caffeine Effervescent Oral Tablet
SCDF · 1536814 -
Aspirin / caffeine Oral Product
SCDG · 1153525
📦 FDA Products & Package NDCs
2 products · 7 package NDCs
7 package NDCs map to RxCUI 1536815 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00280-0084-01 | 10 POUCH in 1 CARTON (0280-0084-01) / 2 TABLET, EFFERVESCEN... | Alka-Seltzer Hangover Relief | Bayer HealthCare LLC. | 2022-02-21 |
| 00280-0084-02 | 18 POUCH in 1 CARTON (0280-0084-02) / 2 TABLET, EFFERVESCEN... | Alka-Seltzer Hangover Relief | Bayer HealthCare LLC. | 2023-04-19 |
| 00280-0084-03 | 60 POUCH in 1 CARTON (0280-0084-03) / 2 TABLET, EFFERVESCEN... | Alka-Seltzer Hangover Relief | Bayer HealthCare LLC. | 2023-04-19 |
| 00280-0084-04 | 2 POUCH in 1 CARTON (0280-0084-04) / 2 TABLET, EFFERVESCENT... | Alka-Seltzer Hangover Relief | Bayer HealthCare LLC. | 2023-04-19 |
| 00280-0084-05 | 1600 POUCH in 1 BOX (0280-0084-05) / 2 TABLET, EFFERVESCENT... | Alka-Seltzer Hangover Relief | Bayer HealthCare LLC. | 2023-05-23 |
| 00280-0084-06 | 30 POUCH in 1 CARTON (0280-0084-06) / 2 TABLET, EFFERVESCEN... | Alka-Seltzer Hangover Relief | Bayer HealthCare LLC. | 2025-10-13 |
| 00280-8260-20 | 10 POUCH in 1 CARTON (0280-8260-20) / 2 TABLET, EFFERVESCEN... | Alka-Seltzer Extra Strength Pain Relief | Bayer HealthCare LLC. | 2026-02-05 |
Observed labelers:
Bayer HealthCare LLC. (7)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.